CLL-directed therapy at time of COVID-19 diagnosis
| Current therapy . | Patients receiving therapy . |
|---|---|
| Total | 90 |
| BTKi | |
| Ibrutinib monotherapy | 43 |
| Acalabrutinib monotherapy | 9 |
| Zanubrutinib monotherapy | 2 |
| Ibrutinib + anti-CD20 mAb | 6 |
| Acalabrutinib + anti-CD20 mAb | 1 |
| Venetoclax | |
| Venetoclax monotherapy | 7 |
| Venetoclax + anti-CD20 mAb | 7 |
| PI3K inhibitor | |
| Idelalisib | 1 |
| Umbralisib | 1 |
| Anti-CD20 mAb | |
| Rituximab | 1 |
| Obinutuzumab | 1 |
| Novel drug combination therapy | |
| BTKi + venetoclax | 2 |
| BTKi + venetoclax + anti-CD20 mAb | 1 |
| BTKi + PI3Ki + anti-CD20 mAb | 3 |
| Venetoclax + PI3Ki + anti-CD20 mAb | 1 |
| BTKi + fludarabine + pembrolizumab | 1 |
| Bendamustine + rituximab | 1 |
| Other | 2 |
| Current therapy . | Patients receiving therapy . |
|---|---|
| Total | 90 |
| BTKi | |
| Ibrutinib monotherapy | 43 |
| Acalabrutinib monotherapy | 9 |
| Zanubrutinib monotherapy | 2 |
| Ibrutinib + anti-CD20 mAb | 6 |
| Acalabrutinib + anti-CD20 mAb | 1 |
| Venetoclax | |
| Venetoclax monotherapy | 7 |
| Venetoclax + anti-CD20 mAb | 7 |
| PI3K inhibitor | |
| Idelalisib | 1 |
| Umbralisib | 1 |
| Anti-CD20 mAb | |
| Rituximab | 1 |
| Obinutuzumab | 1 |
| Novel drug combination therapy | |
| BTKi + venetoclax | 2 |
| BTKi + venetoclax + anti-CD20 mAb | 1 |
| BTKi + PI3Ki + anti-CD20 mAb | 3 |
| Venetoclax + PI3Ki + anti-CD20 mAb | 1 |
| BTKi + fludarabine + pembrolizumab | 1 |
| Bendamustine + rituximab | 1 |
| Other | 2 |